Kolosis BIO Introduces New Surgical Biologic, APEXecm

Kolosis BIO has expanded its targeted solutions portfolio with the debut of APEXecm, a next-generation, allogenic extracellular matrix featuring the company’s proprietary Mini Tile Matrix configuration.

The Mini Tile Matrix is engineered to deliver consistent precision, adaptability, and ease of use in demanding surgical environments. Comprised of collagen, proteoglycans, and native ECM structural proteins, APEXecm protects and supports the natural wound-healing environment for high-risk surgical patients.

The Mini Tile Matrix format addresses a well-documented surgical need for a solution that performs predictably under the variable conditions of live procedures. APEXecm answers such a requirement with a unique configuration that is both intentional and innovative.

“APEXecm is exactly the kind of technology Kolosis was built to bring to market—clinically differentiated, purposefully designed, and developed because it represents the best available answer to a need surgeons have clearly defined,” Kolosis BIO CEO Collin Begley said. “It reflects our commitment to raising the standard for what a dedicated surgical biologics company can deliver.”

APEXecm further expands Kolosis’s portfolio, which spans orthobiologics, advanced wound biologics, and cardiac surgery solutions.

Kolosis BIO is a pure-play biologics company delivering evidence-driven solutions that improve surgical outcomes. With a portfolio spanning advanced bone grafting, cardiac solutions, and surgical incision management, Kolosis brings focus and expertise to the commercialization of biologic technologies.